{"id":5401,"date":"2025-12-24T15:49:52","date_gmt":"2025-12-24T12:49:52","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5401"},"modified":"2025-12-24T15:57:40","modified_gmt":"2025-12-24T12:57:40","slug":"italfarmaco-jcr-pharmaceuticals-duvyzat-givinostat-japan","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/italfarmaco-jcr-pharmaceuticals-duvyzat-givinostat-japan\/","title":{"rendered":"Italfarmaco ve JCR Pharmaceuticals, Japonya'da Duvyzat (Givinostat) i\u00e7in Ticarile\u015ftirme Anla\u015fmas\u0131 ve Nadir Hastal\u0131klar Alan\u0131nda Stratejik \u0130\u015f Birli\u011fi Duyurdu"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Italfarmaco ve JCR Pharmaceuticals, Japonya&#039;da Duvyzat (Givinostat) adl\u0131 ilac\u0131n geli\u015ftirilmesi ve ticarile\u015ftirilmesi i\u00e7in \u00f6zel bir lisans anla\u015fmas\u0131 imzalad\u0131klar\u0131n\u0131 duyurdu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Anla\u015fma \u015fartlar\u0131na g\u00f6re, JCR, Japonya&#039;da Duchenne kas distrofisi (DMD) tedavisi i\u00e7in givinostat&#039;\u0131n ticarile\u015ftirilmesi konusunda m\u00fcnhas\u0131r haklara sahip olacak ve klinik geli\u015ftirme faaliyetlerinin yerel y\u00fcr\u00fct\u00fclmesinden ve d\u00fczenleyici ba\u015fvurulardan sorumlu olacakt\u0131r. <a href=\"https:\/\/dmdwarrior.com\/tr\/duvyzat-givinostat-nonsteroidal-drug\/\" target=\"_blank\" data-type=\"post\" data-id=\"3957\" rel=\"noreferrer noopener\">Givinostat nedir?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Givinostat (ABD, \u0130ngiltere ve AB&#039;de Duvyzat\u00ae olarak pazarlanmaktad\u0131r), altta yatan distrofin gen mutasyonundan ba\u011f\u0131ms\u0131z olarak DMD&#039;yi tedavi etmek i\u00e7in Italfarmaco taraf\u0131ndan geli\u015ftirilen, a\u011f\u0131zdan uygulanan bir histon deasetilaz inhibit\u00f6r\u00fcd\u00fcr. ABD, AB ve \u0130ngiltere dahil olmak \u00fczere bir\u00e7ok b\u00fcy\u00fck pazarda ruhsat alm\u0131\u015ft\u0131r; \u015fu anda Japonya&#039;da onayl\u0131 de\u011fildir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Anla\u015fma ayr\u0131ca, nadir hastal\u0131klar\u0131n tedavisi i\u00e7in ortak f\u0131rsatlar\u0131 ara\u015ft\u0131rmak \u00fczere iki \u015firket aras\u0131nda daha geni\u015f kapsaml\u0131 bir stratejik i\u015f birli\u011fi de kuruyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cItalfarmaco Ba\u015fkan Yard\u0131mc\u0131s\u0131 ve \u0130\u015f ve Portf\u00f6y Geli\u015ftirme Ba\u015fkan\u0131 Antonio Nardi, \u201dBu ortakl\u0131k, givinostat&#039;a eri\u015fimi geni\u015fletme ve nadir hastal\u0131klardaki etkimizi derinle\u015ftirme y\u00f6n\u00fcndeki k\u00fcresel stratejimizde \u00f6nemli bir kilometre ta\u015f\u0131d\u0131r\u201c dedi. \u201dJCR&#039;nin inovasyona olan ba\u011fl\u0131l\u0131\u011f\u0131, g\u00fc\u00e7l\u00fc yerel uzmanl\u0131\u011f\u0131 ve hasta merkezli bilime odaklanmas\u0131, onlar\u0131 yaln\u0131zca Japonya&#039;da de\u011fil, k\u00fcresel olarak da nadir hastal\u0131k portf\u00f6ylerimizin geni\u015flemesi i\u00e7in ideal bir ortak haline getiriyor.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Devam\u0131n\u0131 oku<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne \u0130\u00e7in Klinik Ara\u015ft\u0131rmalar (T\u00fcm Ara\u015ft\u0131rmalar\u0131n Listesi)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Italfarmaco and JCR Pharmaceuticals announced an exclusive licensing agreement for the development and commercialisation of Duvyzat (Givinostat) in Japan. Under the terms of the agreement, JCR receives exclusive rights to commercialise givinostat for the treatment of Duchenne muscular dystrophy (DMD) in Japan and will be responsible for the local execution of clinical development activities, as [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5402,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[46,47,311,142,385],"class_list":["post-5401","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-duvyzat","tag-givinostat","tag-italfarmaco","tag-japan","tag-jcr-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=5401"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5401\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/5402"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=5401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=5401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=5401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}